Swiss National Bank
ALGS icon

Swiss National Bank’s Aligos Therapeutics ALGS Stock Holding History

Swiss National Bank’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,248
Closed -$121K – 2742
2022
Q1 		$121K Hold
2,248
– – ﹤0.01% 2687
2021
Q4 		$667K Hold
2,248
– – ﹤0.01% 2599
2021
Q3 		$872K Buy
2,248
+904
+67% +$358K ﹤0.01% 2473
2021
Q2 		$685K Buy
+1,344
New +$857K ﹤0.01% 2587

Other funds holding ALGS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Swiss National Bank's ALGS Position: Q2 2022 in Review

Swiss National Bank sold out of Aligos Therapeutics (ALGS) in Q2 2022, closing a stake of 2,248 shares — an estimated $121K sold.

Swiss National Bank first reported a position in ALGS in Q2 2021 and held it in 4 quarters. The position peaked at $872K in Q3 2021. 59 funds tracked by Wall St. Rank hold ALGS as of Q2 2022.

  • Swiss National Bank reported no remaining Aligos Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Swiss National Bank sold 2,248 Aligos Therapeutics shares in Q2 2022, an estimated $121K.
  • Swiss National Bank first reported a position in Aligos Therapeutics in Q2 2021 and held it in 4 quarters.
  • Swiss National Bank's Aligos Therapeutics position peaked at $872K in Q3 2021.
  • 59 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q2 2022.

Based on Swiss National Bank's 13F filing for Q2 2022, filed 9 Aug 2022.